We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Janssen Nabs Second FDA Breakthrough Designation for Depression Therapy
Janssen Nabs Second FDA Breakthrough Designation for Depression Therapy
The FDA awarded Janssen’s esketamine a second breakthrough designation for major depressive disorder with imminent risk of suicide, adding a second potential indication for the investigational compound.